(NASDAQ: PAHC) Phibro Animal Health's forecast annual revenue growth rate of 5.86% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.53%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.83%.
Phibro Animal Health's revenue in 2025 is $1,296,215,000.On average, 3 Wall Street analysts forecast PAHC's revenue for 2026 to be $59,398,719,302, with the lowest PAHC revenue forecast at $59,121,388,356, and the highest PAHC revenue forecast at $59,556,435,570. On average, 3 Wall Street analysts forecast PAHC's revenue for 2027 to be $60,221,551,544, with the lowest PAHC revenue forecast at $58,979,236,993, and the highest PAHC revenue forecast at $60,998,621,343.
In 2028, PAHC is forecast to generate $62,584,985,159 in revenue, with the lowest revenue forecast at $62,539,303,783 and the highest revenue forecast at $62,644,002,093.